Lonza and BioWa have granted Pfizer the right to use their Potelligent CHOK1SV cell line technology in the research and development of antibodies. The Potelligent CHOK1SV cell line can be used to develop antibodies that function in whole blood and have cytotoxic effects even at low antigen levels.
